Cosmas Giallourakis
President chez Stylus Medicine, Inc.
Profil
Cosmas Giallourakis is the founder of Design Pharmaceuticals, Inc. founded in 2019.
He is currently a Venture Partner at RA Capital Management LP (Private Equity) since 2021 and the President of Stylus Medicine, Inc. He previously worked as a Director at Takeda Pharmaceutical Co., Ltd.
from 2016 to 2019.
Mr. Giallourakis has an undergraduate degree from Massachusetts Institute of Technology and a doctorate from New Jersey Medical School.
Postes actifs de Cosmas Giallourakis
| Sociétés | Poste | Début |
|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01/11/2021 |
Stylus Medicine, Inc.
 Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | President | - |
Anciens postes connus de Cosmas Giallourakis
| Sociétés | Poste | Fin |
|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Directeur/Membre du Conseil | 31/08/2019 |
Design Pharmaceuticals, Inc.
 Design Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Design Pharmaceuticals, Inc. harnesses nature's chemistry to develop breakthrough therapeutics. The company is based in Cambridge, MA. The company uses engineering-inspired biotechnologies to redesign the process of small molecule-based drug discovery and development, saving time and costs. The company's platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals' cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains, further accelerating lead compound optimization. The company's business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. The company was founded by Dirk Löffert, Cosmas Giallourakis, Marnix Medema, Rob Nicol, Noah W. Palm, Michael Jewett, Andrew Griffiths. Dirk Löffert has been the CEO since incorporation. | Fondateur | - |
Formation de Cosmas Giallourakis
| Massachusetts Institute of Technology | Undergraduate Degree |
| New Jersey Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Design Pharmaceuticals, Inc.
Design Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Design Pharmaceuticals, Inc. harnesses nature's chemistry to develop breakthrough therapeutics. The company is based in Cambridge, MA. The company uses engineering-inspired biotechnologies to redesign the process of small molecule-based drug discovery and development, saving time and costs. The company's platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals' cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains, further accelerating lead compound optimization. The company's business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. The company was founded by Dirk Löffert, Cosmas Giallourakis, Marnix Medema, Rob Nicol, Noah W. Palm, Michael Jewett, Andrew Griffiths. Dirk Löffert has been the CEO since incorporation. | Commercial Services |
Stylus Medicine, Inc.
Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Health Technology |